Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Colorectal Cancer

Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Arlington, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Arlington, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
El Paso, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
El Paso, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Fort Worth, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Houston, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Paris, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Paris, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Plano, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Tyler, TX
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Tyler, TX
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
American Fork, UT
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
American Fork, UT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Bountiful, UT
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Bountiful, UT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Murray, UT
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Murray, UT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Provo, UT
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Provo, UT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
West Jordan, UT
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
West Jordan, UT
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Roanoke, VA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Roanoke, VA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Vancouver, WA
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Vancouver, WA
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/15/2018
mi
from
Bentleigh East,
Study of Ruxolitinib in Colorectal Cancer Patients
A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/15/2018
mi
from
Bentleigh East,
Click here to add this to my saved trials
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
A Phase I Clinical Trial of MEK162 in Combination With FOLFOX in Patients With Advanced Metastatic Colorectal Cancer Who Failed Prior Standard Therapy
Status: Enrolling
Updated:  1/23/2018
City of Hope Medical Center
mi
from
Duarte, CA
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
A Phase I Clinical Trial of MEK162 in Combination With FOLFOX in Patients With Advanced Metastatic Colorectal Cancer Who Failed Prior Standard Therapy
Status: Enrolling
Updated: 1/23/2018
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Randomized Phase 1/2 Evaluation of Neoadjuvant Administration of a Chemokine-Modulatory Regimen in Patients With Recurrent Resectable Colorectal Cancer
Status: Enrolling
Updated:  1/24/2018
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Randomized Phase 1/2 Evaluation of Neoadjuvant Administration of a Chemokine-Modulatory Regimen in Patients With Recurrent Resectable Colorectal Cancer
Status: Enrolling
Updated: 1/24/2018
UPMC - Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
The CHOICE Registry
The CHOICE Registry: A Research Initiative Examining Clinical, Economic, and Humanistic Outcomes in the Management of Metastatic Colorectal Cancer
Status: Enrolling
Updated:  1/26/2018
Ingalls Memorial Hospital
mi
from
Harvey, IL
The CHOICE Registry
The CHOICE Registry: A Research Initiative Examining Clinical, Economic, and Humanistic Outcomes in the Management of Metastatic Colorectal Cancer
Status: Enrolling
Updated: 1/26/2018
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Mayo Clinic Arizona - Cancer Clinical Research Unit
mi
from
Scottsdale, AZ
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Mayo Clinic Arizona - Cancer Clinical Research Unit
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Stanford Cancer Center - Stanford University
mi
from
Stanford, CA
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Stanford Cancer Center - Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine
mi
from
New York, NY
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Icahn School of Medicine at Mount Sinai Hess Center for Science and Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Oregon Health and Science University
mi
from
Portland, OR
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
University of Pennsylvania:Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
Mary Crowley Cancer Research Centers - Medical City
mi
from
Dallas, TX
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
Mary Crowley Cancer Research Centers - Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
University of Virginia Health System
mi
from
Charlottesville, VA
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated:  1/29/2018
The Mayo Clinic
mi
from
Rochester, MN
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
A Phase 1, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors
Status: Enrolling
Updated: 1/29/2018
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Colorectal Cancer Screening for Cancer Survivors
Colorectal Cancer Screening in Cancer Survivors Treated With Radiation Therapy
Status: Enrolling
Updated:  1/30/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Colorectal Cancer Screening for Cancer Survivors
Colorectal Cancer Screening in Cancer Survivors Treated With Radiation Therapy
Status: Enrolling
Updated: 1/30/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Colorectal Cancer Screening for Cancer Survivors
Colorectal Cancer Screening in Cancer Survivors Treated With Radiation Therapy
Status: Enrolling
Updated:  1/30/2018
University Health Network
mi
from
Toronto,
Colorectal Cancer Screening for Cancer Survivors
Colorectal Cancer Screening in Cancer Survivors Treated With Radiation Therapy
Status: Enrolling
Updated: 1/30/2018
University Health Network
mi
from
Toronto,
Click here to add this to my saved trials
Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer <pT2
Status: Enrolling
Updated:  1/30/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer
Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer <pT2
Status: Enrolling
Updated: 1/30/2018
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Neo-Adjuvant FOLFOX for Rectal Carcinoma
A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6
Status: Enrolling
Updated:  2/1/2018
Beth Israel Med Ctr
mi
from
New York, NY
Neo-Adjuvant FOLFOX for Rectal Carcinoma
A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6
Status: Enrolling
Updated: 2/1/2018
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Neo-Adjuvant FOLFOX for Rectal Carcinoma
A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6
Status: Enrolling
Updated:  2/1/2018
St Luke's - Roosevelt Hospital Center
mi
from
New York, NY
Neo-Adjuvant FOLFOX for Rectal Carcinoma
A Phase II Open- Labeled, Prospective Study to Determine the Efficacy of Pre- Operative Chemotherapy With Six Cycles of Modified FOLFOX 6 Followed by Total Mesorectal Excision (TME) Followed by an Additional Six Cycles of FOLFOX 6
Status: Enrolling
Updated: 2/1/2018
St Luke's - Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Open Door Health Center
mi
from
Arcata, CA
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Open Door Health Center
mi
from
Arcata, CA
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Mosaic Medical
mi
from
Bend, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Mosaic Medical
mi
from
Bend, OR
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Benton and Linn County Health Centers
mi
from
Corvallis, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Benton and Linn County Health Centers
mi
from
Corvallis, OR
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Virginia Garcia Memorial Health Center
mi
from
Hillsboro, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Virginia Garcia Memorial Health Center
mi
from
Hillsboro, OR
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
La Clinica Health Care
mi
from
Medford, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
La Clinica Health Care
mi
from
Medford, OR
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Community Health Center
mi
from
Medford, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Community Health Center
mi
from
Medford, OR
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Multnomah County Health Department
mi
from
Portland, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Multnomah County Health Department
mi
from
Portland, OR
Click here to add this to my saved trials
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated:  2/2/2018
Oregon Health and Science University
mi
from
Scappoose, OR
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Strategies and Opportunities to Stop Colon Cancer in Priority Populations
Status: Enrolling
Updated: 2/2/2018
Oregon Health and Science University
mi
from
Scappoose, OR
Click here to add this to my saved trials
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
A Phase II, Open-label, Multicentre Study of PM060184 in Patients With Advanced Colorectal Cancer After Standard Treatment.
Status: Enrolling
Updated:  2/2/2018
US017
mi
from
Los Angeles, CA
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
A Phase II, Open-label, Multicentre Study of PM060184 in Patients With Advanced Colorectal Cancer After Standard Treatment.
Status: Enrolling
Updated: 2/2/2018
US017
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
A Phase II, Open-label, Multicentre Study of PM060184 in Patients With Advanced Colorectal Cancer After Standard Treatment.
Status: Enrolling
Updated:  2/2/2018
CA001
mi
from
Toronto,
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
A Phase II, Open-label, Multicentre Study of PM060184 in Patients With Advanced Colorectal Cancer After Standard Treatment.
Status: Enrolling
Updated: 2/2/2018
CA001
mi
from
Toronto,
Click here to add this to my saved trials
Screening for Familial Colorectal Cancer (CRC) Patients
Screening and Risk Communication for First Degree Relatives of Colorectal Cancer Patients
Status: Enrolling
Updated:  2/6/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Screening for Familial Colorectal Cancer (CRC) Patients
Screening and Risk Communication for First Degree Relatives of Colorectal Cancer Patients
Status: Enrolling
Updated: 2/6/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy
Pilot Study Assessing the Correlation Between Telomere Length and Chemotherapy- Related Toxicity Among Early Stage and Metastatic Colorectal Patients Over the Age of 70
Status: Enrolling
Updated:  2/6/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal Cancer Undergoing Chemotherapy
Pilot Study Assessing the Correlation Between Telomere Length and Chemotherapy- Related Toxicity Among Early Stage and Metastatic Colorectal Patients Over the Age of 70
Status: Enrolling
Updated: 2/6/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers
Status: Enrolling
Updated:  2/7/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers
Status: Enrolling
Updated: 2/7/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors
ICCS Directed Physical Activity Enhancement for Colon Cancer Survivors
Status: Enrolling
Updated:  2/8/2018
The Hartford Hospital
mi
from
Hartford, CT
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors
ICCS Directed Physical Activity Enhancement for Colon Cancer Survivors
Status: Enrolling
Updated: 2/8/2018
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors
ICCS Directed Physical Activity Enhancement for Colon Cancer Survivors
Status: Enrolling
Updated:  2/8/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Interactive Cancer Communication System (ICCS) Directed Physical Activity Enhancement for Colon Cancer Survivors
ICCS Directed Physical Activity Enhancement for Colon Cancer Survivors
Status: Enrolling
Updated: 2/8/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials